The Future of Peptide‐based Drugs
- Journal
- Chemical Biology & Drug Design
In The Last Decade
doi.org/10.1111/cbdd.12055 →Countries where authors are citing The Future of Peptide‐based Drugs
This map shows the geographic impact of The Future of Peptide‐based Drugs. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by The Future of Peptide‐based Drugs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites The Future of Peptide‐based Drugs more than expected).
Fields of papers citing The Future of Peptide‐based Drugs
This network shows the impact of The Future of Peptide‐based Drugs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the The Future of Peptide‐based Drugs.
About The Future of Peptide‐based Drugs
This paper, published in 2012, received 1.6k indexed citations . Written by David J. Craik, David P. Fairlie, Spiros Liras and David A. Price covering the research area of Molecular Biology and Organic Chemistry. It is primarily cited by scholars working on Molecular Biology (1.2k citations), Organic Chemistry (380 citations) and Microbiology (285 citations). Published in Chemical Biology & Drug Design.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1111/cbdd.12055.